What Dexcom's FY2025 10-K says: 10 signals
Dexcom filed its latest 10-K with the SEC on Feb 12, 2026. It discusses product launch, capacity constraint and channel shift.
Public (DXCM)Medical Equipment Manufacturing10,000+ employeesdexcom.comLinkedIn
- Filed
- Feb 12, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 9
What Dexcom's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 10 signals
Dexcom launched Stelo, its first over-the-counter glucose biosensor, in August 2024
This launch expands Dexcom's addressable market beyond prescribed diabetes patients to general consumers interested in metabolic health, creating a need for new direct-to-consumer marketing, e-commerce, and distribution strategies.
Dexcom launched its new G7 15 Day CGM system in late 2025 after receiving FDA approval
The launch of this new, longer-wear device is a key part of the company's product roadmap to improve user convenience and defend market share, triggering significant spending on go-to-market activities, sales training, and inventory management.
Facing administrative challenges and coverage gaps in reimbursement from third-party payors
Dexcom reports frequent administrative difficulties and a lack of broad contractual coverage in securing reimbursement for its products.
Dexcom at risk of product withdrawal after receiving an FDA warning letter
The company must respond to an FDA warning letter and ensure compliance with ongoing regulatory requirements to avoid product restrictions or market withdrawal.
The company's strategy involves integrating its technology with partners' insulin pumps, smart pens, and wearables like Apple Watch and Garmin.
cloudmobile appAppleGarmin
Dexcom warns insufficient manufacturing capabilities could limit future growth
The company states that its ability to grow is directly threatened if its manufacturing capacity cannot produce an adequate supply of products at required quality levels.
Identifies decreasing product prices as a material risk to financial results
Management explicitly states that falling prices for its products could have a material adverse effect on business and cash flows if not offset by cost reductions.
Facing increased costs and liability risk from data privacy laws like HIPAA
The company is exposed to risks from complex and evolving data privacy regulations, including HIPAA, which could result in monetary penalties and increased operational costs.
cloud
Expanding use of Dexcom Clarity cloud platform for data sharing and analytics
Dexcom's strategy relies on its Dexcom Clarity cloud platform to transmit, store, and share sensitive glucose data with patients and caregivers.
cloudAppleGoogle
Showing 9 of 10 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Dexcom with the Signal API
One POST /v1/companies/enrich call with dexcom.com returns Dexcom 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"dexcom.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Dexcom 10-K
When did Dexcom file its latest 10-K?
What does Dexcom's latest 10-K say about product launch?
Where can I find Dexcom's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .